Last reviewed · How we verify
Pegvisomant/ Sandostatin LAR
Pegvisomant is a growth hormone receptor antagonist that blocks GH signaling, while Sandostatin LAR is a somatostatin analog that inhibits growth hormone secretion.
Pegvisomant is a growth hormone receptor antagonist that blocks GH signaling, while Sandostatin LAR is a somatostatin analog that inhibits growth hormone secretion. Used for Acromegaly in patients inadequately controlled by surgery and/or radiotherapy, or as primary therapy when surgery/radiotherapy not an option.
At a glance
| Generic name | Pegvisomant/ Sandostatin LAR |
|---|---|
| Sponsor | Pfizer |
| Drug class | Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR) |
| Target | Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Pegvisomant competitively antagonizes the growth hormone receptor, preventing GH-mediated effects on target tissues. Sandostatin LAR (octreotide) is a long-acting somatostatin analog that suppresses growth hormone and insulin-like growth factor-1 (IGF-1) secretion from the anterior pituitary. Together, they provide complementary mechanisms to reduce circulating GH and IGF-1 levels in acromegaly.
Approved indications
- Acromegaly in patients inadequately controlled by surgery and/or radiotherapy, or as primary therapy when surgery/radiotherapy not an option
Common side effects
- Injection site reactions
- Elevated liver transaminases
- Hyperglycemia
- Arthralgia
- Fatigue
- Gallstones (with octreotide)
Key clinical trials
- Acromegaly Combination Treatment Study (NA)
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (PHASE4)
- Pasireotide LAR and Pegvisomant Study in Acromegaly (PHASE4)
- Pegvisomant And Sandostatin LAR Combination Study (PHASE4)
- A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegvisomant/ Sandostatin LAR CI brief — competitive landscape report
- Pegvisomant/ Sandostatin LAR updates RSS · CI watch RSS
- Pfizer portfolio CI